|
2024 Conference Publication A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysisTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Peter, Borchmann, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Torzan, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7056 |
|
2024 Conference Publication A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysisTimmerman, John, Lavie, David, Peter, Borchmann, Gregory, Gareth P., Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Johnson, Nathalie A. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7055 |
|
2024 Conference Publication First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led studyChong, Geoffrey, Palmer, Jodie, Barraclough, Allison, Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza Anne (2024). First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.tps7092 |
|
2024 Conference Publication First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO studyChong, Geoffrey, Lee, Denise, Lee, Sze Ting, Grobler, Anneke, Khor, Richard, Campbell, Belinda A., Thachil, Thanuja, Manos, Kate, Martynchyk, Arina, Douglas, Genevieve, Keane, Colm, Palmer, Jodie and Hawkes, Eliza Anne (2024). First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7070 |
|
2023 Conference Publication Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 StudyTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182019 |
|
2023 Conference Publication Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated StudyChong, Geoff, Palmer, Jodie B., Barraclough, Allison A., Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza A. (2023). Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173110 |
|
2023 Conference Publication Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 StudyJohnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182128 |
|
2023 Conference Publication Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin LymphomaJohnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin Lymphoma. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971156.02746.02 |
|
2023 Conference Publication Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie, Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Luigi Zinzani, Pier, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 Treatment. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971168.59900.67 |
|
2023 Conference Publication T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor StudyKoldej, Rachel, Barraclough, Allison, Ting Lee, Sze, Morgan, Huw, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Ting, Stephen, Churilov, Leonid, Ritchie, David and Hawkes, Eliza A. (2023). T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor Study. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971812.42966.2d |
|
2023 Conference Publication Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) StudyShaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoff, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A (2023). Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) Study. EHA2023, Online, 8 - 15 June 2023. Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/01.hs9.0000971668.24670.ab |
|
2023 Conference Publication Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) StudyShaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., Johnston, A., Cheah, C., Hamad, N., Simpson, J., Barraclough, A., Ku, M., Viiala, N., Ratnasingam, S., Armytage, T., Cochrane, T., Chong, G., Lee, D., Manos, K., Keane, C., Wallwork, S., Opat, S. and Hawkes, E. (2023). Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) Study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3165_572 |
|
2023 Conference Publication Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapseSwain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191 |
|
2023 Conference Publication Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” studyHawkes, E. A., Palmer, J., Chong, G., Lee, S., Keane, C., Shortt, J., Scott, A. M., Churilov, L., Macmanus, M., Smith, C., Barraclough, A., Khor, R. and Manos, K. (2023). Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_448 |
|
2023 Conference Publication An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatmentLavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P. and Timmerman, J. (2023). An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_263 |
|
2023 Conference Publication Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphomaTobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189 |
|
2023 Conference Publication T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR studyKoldej, R. M., Barraclough, A., Lee, S. T., Morgan, H., Holzwart, N., Koshy, M., Smith, C., Chong, G., Gilbertson, M., Keane, C., Ting, S., Churilov, L., Ritchie, D. S. and Hawkes, E. A. (2023). T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_183 |
|
2022 Conference Publication Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin LymphomaJohnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166846 |
|
2022 Conference Publication Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166670 |
|
2022 Conference Publication Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin LymphomaBorchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890812.66186.e8 |
